Awareness of available IP options is key to building a robust
and investable patent portfolio, which can drive R&D, thereby
allowing for better drugs and diagnostics
At the core of any new pharmaceutical company – or the
start of a new project for a more established pharma company
– is an innovative piece of science that is believed to lead
to new and beneficial healthcare products. It will take the
combined efforts of a wide range of scientists, researchers, and
clinical and regulatory experts to push these new healthcare
products towards the market. Often, the innovation provides one or
more new drug candidates, which the pharma company moves along the
stages of R&D towards having a new blockbuster drug on the
market or is aimed at earlier or better detection of disease and
the research focuses on validating and refining the sensitivity and
selectivity of the diagnostic tests.
